Case report: Complete restoration of the HPA axis function in Cushing’s disease with drug treatment

Case report: Complete restoration of the HPA axis function in Cushing’s disease with drug treatment

This report describes a rare case of a 20-year-old man with an ACTH- and prolactin-secreting invasive pituitary macroadenoma causing hyperprolactinemia and Cushing’s disease. He was later found to have an AIP mutation. Treatment with cabergoline (1.5 mg weekly) normalized prolactin concentrations an...

Full description

Bibliographic Details
Main Authors:	Joanne Thanh-Tâm Nguyen, Amandine Ferrière, Antoine Tabarin
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-02-01
Series:	Frontiers in Endocrinology
Subjects:	AIP mutation pituitary macroadenoma prolactinoma Cushing’s disease cabergoline remission
Online Access:	https://www.frontiersin.org/articles/10.3389/fendo.2024.1337741/full

Similar Items

The clinical and therapeutic profiles of prolactinomas associated with germline pathogenic variants in the aryl hydrocarbon receptor interacting protein (AIP) gene
by: Laurent Vroonen, et al.
Published: (2023-08-01)

Management of prolactinoma with cabergoline treatment in a pregnant woman during her entire pregnancy
by: Sukhwinder Kaur Bajwa, et al.
Published: (2011-01-01)

Stroke due to extrinsic compression of the internal carotide secondary to invasive hypophyseal macroadenoma with pituitary Apoplejia: A case report and literature review
by: Jorge Wilmar Tejada-Marin, M.D., et al.
Published: (2023-09-01)

Complicated Clinical Course in Incipient Gigantism Due to Treatment-resistant Aryl Hydrocarbon Receptor–Interacting Protein–mutated Pediatric Somatotropinoma
by: Selveta Sanne van Santen, MD, MSc, et al.
Published: (2022-05-01)

Treatment-resistant Cushing disease and acromegaly in a young woman: A case of functional pituitary macroadenoma
by: Ibrahim Khalil, MBBS, et al.
Published: (2025-04-01)

Macroprolactinoma in a 14-Year-Old Girl in the Northeast of Iran: A Case Report
by: Habibe Sadat Shakeri, et al.
Published: (2024-03-01)

Clinical and Laboratory Characteristics of Hyperprolactinemia in Children and Adolescents: National Survey
by: Erdal Eren, et al.
Published: (2019-06-01)

Clinical Outcome of Invasive Pituitary Prolactinomas Treated with Cabergoline
by: Bassam M Flamerz Arkawazi
Published: (2020-01-01)

Resistance to Dopamine Agonists in Pituitary Tumors: Molecular Mechanisms
by: Claudia Pivonello, et al.
Published: (2022-01-01)

Pregnancy‐induced progressive change of prolactin‐secreting macroadenoma with the development of bitemporal hemianopia and severe headache
by: Sirinart Sirilert, et al.
Published: (2019-07-01)

Hyperprolactinemia in children and adolescents and longterm follow-up results of prolactinoma cases: a single-centre experience
by: Tuğba Kontbay, et al.
Published: (2022-10-01)

Long-term cardiac (valvulopathy) safety of cabergoline in prolactinoma
by: Shruti Khare, et al.
Published: (2017-01-01)

No link to cardiac valvulopathy was seen in cabergoline treated patients
by: K Dharshini, et al.
Published: (2012-10-01)

VISUAL FIELD DEFECTS SECONDARY TO CABERGOLINE USE IN A PATIENT WITH PITUITARY TUMOR
by: sylvia andrea araneda, et al.
Published: (2015-02-01)

Caracterización clínico-epidemiológica de pacientes con hiperprolactinemia y adenomas hipofisiarios productores de prolactina
by: Sofía Isea, et al.
Published: (2022-04-01)

Aripiprazole use as a cause of dopamine agonist failure in the treatment of prolactinomas
by: Edward Mignone, et al.
Published: (2025-01-01)

Makroprolaktinoma da Kabergolin Tedavisinin Etkinliği
by: Derya Buluş
Published: (2017-09-01)

Temozolomide in treatment resistant prolactinomas
by: V. N. Shree, et al.
Published: (2018-08-01)

Early Prediction of Long-Term Response to Cabergoline in Patients with Macroprolactinomas
by: Youngki Lee, et al.
Published: (2014-09-01)

Long-term efficacy and safety of subcutaneous pasireotide alone or in combination with cabergoline in Cushing’s disease
by: Richard A. Feelders, et al.
Published: (2023-10-01)

Primary signs of pituitary macroadenomas of diff erent hormonal activity and specialists to whom patients referred at the fi rst time
by: Y. G. Krivosheeva, et al.
Published: (2022-03-01)

Comparative efficacy and safety of generic (Bergolak) vs. brand cabergoline in the treatment of patients with prolactin-secreting tumors
by: Galina Afanas'evna Melnichenko, et al.
Published: (2015-04-01)

The course of pregnancy and delivery in patients with prolactinoma during treatment with cabergoline
by: Larisa Dzeranova, et al.
Published: (2016-11-01)

Cabergoline-induced tricuspid regurgitation: Case report and review of literature
by: Mohammad Hayat Bhat, et al.
Published: (2011-01-01)

Spontaneous reduction of prolactinoma post cabergoline withdrawal
by: Sampath Kumar Venkatesh, et al.
Published: (2012-01-01)

Giant cabergoline-resistant prolactinoma in a man who presented with a psychotic episode during treatment: a case report
by: Luiz Augusto Casulari, et al.
Published: (2019-06-01)

Cabergoline-associated valvulopathy of the tricuspid valve in the treatment of prolactinoma
by: Annabelle G Hayes, et al.
Published: (2023-01-01)

Sparsely Granulated Corticotroph Pituitary Macroadenoma Presenting With Pituitary Apoplexy Resulting in Remission of Hypercortisolism
by: Tao Liu, MD, et al.
Published: (2022-07-01)

PAM variants in patients with thyrotrophinomas, cyclical Cushing’s disease and prolactinomas
by: Sunita M. C. De Sousa, et al.
Published: (2023-11-01)

Pathogenesis, diagnosis and current treatment of prolactinoma: a review of the literature
by: Monika Szyszka, et al.
Published: (2024-07-01)

Pituitary macroadenomas in childhood and adolescence: a clinical analysis of 7 patients
by: Cristina Aguilar-Riera, et al.
Published: (2023-10-01)

Russian registry of hypothalamic and pituitary tumors: clinical and statistical analysis for 01.01.2023
by: A. S. Lutsenko, et al.
Published: (2024-01-01)

Pituitary Adenomas: From Diagnosis to Therapeutics
by: Samridhi Banskota, et al.
Published: (2021-04-01)

Clinical and genetic aspects of familial isolated pituitary adenomas
by: Vladimir Vasilev, et al.
Published: (2012-01-01)

A clinical case of effective treatment of giant prolactinoma in patient with morbid obesity
Published: (2014-06-01)

Treatment of hyperprolactinemia in women: A Position Statement from the Brazilian Federation of Gynecology and Obstetrics Associations (Febrasgo) and the Brazilian Society of Endocrinology and Metabolism (SBEM)
by: Cristina Laguna Benetti-Pinto, et al.
Published: (2024-06-01)

Resistance to dopamine agonists in the treatment of prolactinomas: diagnostic criteria, mechanisms and ways to overcome it
by: Irena A. Ilovayskaya, et al.
Published: (2023-12-01)

A pharmacoeconomic analysis from Italian guidelines for the management of prolactinomas
by: Michele Basile, et al.
Published: (2024-01-01)

Subarachnoid Hemorrhage Due to Rupture of an Intracavernous Carotid Artery Aneurysm Coexisting with a Prolactinoma under Cabergoline Treatment
by: Nobuyuki Akutsu, et al.
Published: (2014-03-01)

Prolactinomas: evolution after menopause
by: Maria Susana Mallea-Gil, et al.